GSK plc (GSK), Thursday announced positive data from a phase II trial for its mRNA seasonal influenza vaccine programme.
The study evaluated the reactogenicity, safety, and immunogenicity of different dose levels of a modified, multivalent vaccine candidate, encoding antigens matched to all three WHO-recommended influenza strains.
The results revealed that pre-defined success criteria were met in both younger and older participants. Additionally, the interim data suggested that the vaccine candidates have an acceptable safety and reactogenicity profile across all mRNA formulations tested.
Based on this data, the biopharma company plans to advance into late-stage clinical development.
Currently, GSK's stock is trading at $43.10, down 1.52 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.